Tianeptine

Tianeptine is an atypical tricyclic antidepressant bearing a dibenzothiazepine nucleus and an aminoheptanoic acid side chain, first synthesized by the Science Union et Cie, Societe Francaise de Recherche Medicale in 1971 and brought to market in France in 1989 by Laboratoires Servier under the brand name Stablon. The compound is approved as an antidepressant in approximately 60 countries, predominantly in Europe, Asia, and Latin America, but is not approved by the United States Food and Drug Administration, Health Canada, or the Australian Therapeutic Goods Administration. Tianeptine was originally classified as a selective serotonin reuptake enhancer on the basis of early microdialysis studies demonstrating increased serotonin clearance from the synaptic cleft, a mechanism diametrically opposite to that of the selective serotonin reuptake inhibitors. This original mechanistic classification was substantially revised by the landmark 2014 report from Gassaway and colleagues, which demonstrated that tianeptine is a moderately potent but highly efficacious and selective full agonist at the mu-opioid receptor (MOR), with Ki of 383 nanomolar and EC50 of 194 nanomolar for G-protein activation relative to DAMGO, and negligible affinity at delta-opioid and kappa-opioid receptors [1]. Subsequent studies confirmed that the behavioral antidepressant effects of tianeptine in rodent forced swim test and tail suspension test models are abolished in mu-opioid receptor knockout mice and are blocked by the opioid antagonist naloxone, establishing the MOR as the primary pharmacological target for the antidepressant activity [2].

A second, mechanistically distinct axis of tianeptine pharmacology involves modulation of glutamatergic neurotransmission and synaptic plasticity. Tianeptine stabilizes surface AMPA receptor populations through a calcium/calmodulin-dependent protein kinase II (CaMKII) dependent mechanism that promotes the binding of the AMPA receptor auxiliary subunit stargazin with postsynaptic density protein 95 (PSD-95), thereby reducing AMPA receptor surface diffusion and restoring long-term potentiation in the hippocampus of stressed animals [3, 4]. Tianeptine prevents corticosterone-induced dispersal of AMPA receptors from the postsynaptic density and blocks stress-induced reductions in hippocampal dendritic arborization, spine density, and neurogenesis. These neuroplastic effects are observed at clinically relevant concentrations and are hypothesized to mediate the sustained antidepressant and anxiolytic efficacy that persists beyond the short plasma half-life of the parent compound.

Pharmacokinetics are characterized by near-complete oral bioavailability (approximately 99 percent), rapid absorption with time to peak plasma concentration of approximately one hour, high plasma protein binding (approximately 95 percent), a short elimination half-life for the parent compound of 2.5 to 3 hours necessitating three-times-daily dosing at the standard 12.5 mg dose, and hepatic metabolism predominantly through beta-oxidation (not cytochrome P450 enzymes) to the active metabolite MC5, which retains mu-opioid agonist activity with an EC50 of 545 nanomolar and has a longer elimination half-life of approximately 7.6 hours [5, 6]. The CYP-independent metabolism limits clinically significant drug-drug interactions relative to other antidepressant classes.

Clinical efficacy in major depressive disorder has been established in multiple randomized controlled trials comparing tianeptine with placebo, imipramine, amitriptyline, fluoxetine, paroxetine, and sertraline. A meta-analysis of five randomized controlled trials encompassing 1,348 patients found no significant difference between tianeptine and SSRIs on the Montgomery-Asberg Depression Rating Scale total score or responder rate [7]. Tianeptine demonstrates a tolerability advantage over classical tricyclic antidepressants, producing significantly fewer cardiovascular, anticholinergic, sedative, and weight-gain adverse events, and a tolerability profile broadly comparable to SSRIs with lower rates of sexual dysfunction [8].

The mu-opioid receptor agonism has introduced a substantial abuse liability signal, particularly in the United States where tianeptine has been marketed as an unregulated dietary supplement and sold at gas stations and convenience stores under brand names such as ZaZa and Tianna. At supratherapeutic doses (typically 10- to 100-fold above the clinical dose), tianeptine produces opioid-type euphoria, physical dependence, and a withdrawal syndrome clinically indistinguishable from classical opioid withdrawal [9]. The FDA has issued public warnings, and as of 2026, at least 15 United States states have scheduled or banned tianeptine [10]. Italy became the first European country to classify tianeptine as a controlled substance in 2020. This monograph reviews the chemistry, synthesis, and structural pharmacology of tianeptine; the dual mu-opioid and glutamatergic mechanisms in molecular detail; the comprehensive pharmacokinetic record; the clinical evidence base across depressive, anxious, and comorbid indications; the sourcing, reconstitution, and handling considerations for laboratory work; the stack-interaction profile; the adverse-event and abuse-liability signal; and a comparative assessment of five antidepressant alternatives against tianeptine on five competency standards.